Skip to main content

Home Future Students Current Students Faculty & Staff Patients Alumni

University of Colorado Denver Hematology, Blood Cancer, Bone Marrow Transplant Program

A-Z Index | Find a Health Care Provider

Contact Us | Maps and Parking

Search:

Clinical Trials

See what human subject trials are accepting applicants

For more information click the study identifier or search the identifier number at clinicaltrials.gov.

Acute Lymphoblastic Leukemia (non transplant)

ClinicalTrials.gov Identifier	Study Title	Study Coordinator
NCT01564784	Pfizer B1931022: An Open-label, Randomized Phase 3 Study of Inotuzumab Ozogamicin Compared to a Defined Investigator's Choice in Adult Patients with Relapsed or Refractory CD22 Positive Acute Lymphoblastic Leukemia (ALL)	Emily Denoncourt 720-848-0566
NCT01132573	A Phase I Study of the Histone Deacetylase Inhibitor Entinostat (SNDX-275, NSC 706995, IND#61198) plus Clofarabine for Philadelphia Chromosome-Negative, Poor Risk Acute Lymphoblastic Leukemia or Bilineage/Biphenotypic Leukemia in Newly Diagnosed Older Adults or in Adults with Relapsed and Refractory Disease	Nicole Adler 720-848-0678

Acute Myeloid Leukemia (non-transplant)

ClinicalTrials.gov Identifier	Study Title	Study Coordinator
NCT01358734	A Phase 2, Multi-Center, Open-label, Randomized, Parallel-Group Study of A Lenalidomide (Revlimid®) Regimen or A Sequential Azacitidine (Vidaza®) plus Lenalidomide (Revlimid®) Regimen Versus Azacitidine (Vidaza®) Regimen for Therapy of Older Subjects with Newly Diagnosed Acute Myeloid Leukemia	Leigh Walzer 720-848-0736
NCT01743859	Celgene RV-AML-PI - 0759: Sequential Treatment with Azacitidine and Lenalidomide for Relapsed and Refractory Patients with Acute Myeloid Leukemia	Leigh Walzer 720-848-0736
NCT01546038	A Phase 1B/2 Study to Evaluate the Safety and Preliminary Efficacy of PF-04449913, an Oral Hedgehog Inhibitor, in Combination with Intensive Chemotherapy, Low Dose Ara-c, or Decitabine in Patients with Acute Myeloid Leukemia or High Risk Myelodyplastic Syndrome	Leigh Walzer 720-848-0736
NCT00840177	S0919, A Phase II Study of Idarubicin and Ara-C in Combination with Pravastatin for Relapsed Acute Myelogenous Leukemia (AML)	Leigh Walzer 720-848-0736
NCT01915498	A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-221 in Subjects with Advanced Hematologic Malignancies with an IDH2 Mutation.	Nichole Adler 720-848-0678 Derek Schatz 720-8480628

NCT01994837 A Phase 2 Study of ABT-199 in Subjects with Acute Myelogenous Leukemia (AML)

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (non transplant)

ClinicalTrials.gov Identifier	Study Title	Study Coordinator
NCT01886859	A Dose Escalation Study of Ibrutinib with Lenalidomide for Relapsed and Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	Nicole Adler 720-848-0678

Hodgkin Lymphoma (non transplant)

No current trials recruiting

Myelodysplastic Syndrome (non transplant)

ClinicalTrials.gov Identifier	Study Title	Study Coordinator
NCT01522976	SWOG S1117: A Randomized Phase II Study of Azacitidine in Combination with Lenalidomide (NSC-7036813) versus Azacitidine Alone versus Azacitidine in Combination with Vorinostat (NSC - 701852) for Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)	Leigh Walzer 720-848-0736
NCT01546038	A Phase 1B/2 Study to Evaluate the Safety and Preliminary Efficacy of PF-04449913, an Oral Hedgehog Inhibitor, in Combination with Intensive Chemotherapy, Low Dose Ara-c, or Decitabine in Patients with Acute Myeloid Leukemia or High Risk Myelodyplastic Syndrome	Leigh Walzer 720-848-0736
NCT01584531	A Phase II, Multicenter, Single-arm Study to Assess the Efficacy and Safety of Oral Rigosertib in Transfusion-dependent Low or Intermediate-1 (Any Cytogenetics) or Trisomy 8 Intermediate-2 Myelodysplastic Syndrome Patients Based on IPSS Classification	Nikki Ayodeji 720-848-0701
NCT01915498	A Phase I, Multicenter, Open-Label, Dose-Escalationa, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-221 in Subjects with Advanced Hematologic Malignancies with an IDH2 Mutation	Nichole Adler 720-848-0678

Myeloma (non transplant)

ClinicalTrials.gov Identifier	Study Title	Study Coordinator
NCT01734928	A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide, Bortezomib and Low-Dose Dexamethasone versus Bortezomib and Low-Dose Dexamethasone in subjects with Relapsed and Refractory Multiple Myeloma	Leigh Walzer, 720-848-0736
NCT01989325	A Multicenter, Randomized, Open-label, Phase 2 Study of Carfilzomib With or Without ARRY-520 in Patients With Advanced Multiple Myeloma	Derek Schatz, 720-848-0628

Non Hodgkin Lymphoma: Follicular & other indolent (non transplant)

ClinicalTrials.Gov Identifier	Study Title	Study Coordinator

NCT01294579	A Phase II Open-Label Study of Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Indolent B-cell Non- Hodgkin’s Lymphoma (B-NHL) Which Has Relapsed after Rituximab or a Rituximab-Containing Therapy	Leigh Walzer 720-848-0736

Non Hodgkin Lymphoma: Mantle Cell (non transplant)

No current trials recruiting

Non Hodgkin Lymphoma: DLBCL and other aggressive (non transplant)

No current trials recruiting

Transplant

ClinicalTrials.Gov Identifier	Study Title	Study Coordinator
NCT00723099	Transplantation of Unrelated Donor Umbilical Cord Blood in Patients with Hematological Malignancies Using a Reduced-intensity Preparative Regimen	Derek Schatz 720-848-0628
NCT01231412	A Randomized Phase II Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD after Unrelated Donor Hematopoietic Cell Transplantation using Nonmyeloablative Conditioning for Patients with Hematologic Malignancies: A Multi-Center Trial	Derek Schatz 720-848-0628
NCT01690520	Multi-center, open-label randomized study of single or double myeloablative cord blood transplantation with or without infusion of off-the-shelf ex vivo expanded cryopreserved cord blood progenitor cells in patients with hematologic malignancies	Derek Schatz 720-848-0628
NCT01841333	A Phase 2 Study of PF-04449913 for the Treatment of Acute Leukemia Patients with High Risk of Post-Allogeneic Stem Cell Transplantation Relapse	Emily Denoncourt 720-848-0566
NCT01610414	GSK 115523: A phase III, randomised, observer-blind, placebo-controlled, multicentre, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of GSK Biologicals' herpes zoster gE/AS01B candidate vaccine when administered intramuscularly on a two-dose schedule to adult autologous haematopoietic stem cell transplant (HCT) recipients.	Derek Schatz 720-848-0628
NCT01769170	Randomized Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase 3 study of the Safety, Tolerability, and Efficacy of CMX001 for the Prevention of Cytomegalovirus (CMV) Infection in CMV-seropositive (R+) Hematolpoietic Stem Cell Transplant Recipients	Derek Schatz 720-848-0628

University of Colorado Denver

© The Regents of the University of Colorado, a body corporate. All rights reserved.

All trademarks are registered property of the University. Used by permission only.